Wolf Popper LLP Files Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd.

NEW YORK, May 01, 2017 -- Wolf Popper LLP has filed a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (NYSE MKT:IMUC), certain of its former and current officers, and other individuals and entities, in the United States District Court for the Central District of California (2:17-cv-03250), on behalf of all persons who purchased or acquired ImmunoCellular common stock on the open market, during the period May 1, 2012 through December 11, 2013, and were damaged thereby.  This action alleges claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

If you are a member of the Class, you may file a motion no later than June 30, 2017 to be appointed lead plaintiff.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Investors who purchased ImmunoCellular common stock during the Class Period and suffered losses are urged to contact Wolf Popper to discuss their rights. 

ImmunoCellular is a development stage company, and its lead product candidate, ICT-107, is a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma multiforme.

The Complaint charges that prior to and throughout the Class Period, defendants developed a scheme to manipulate and artificially inflate the stock price of ImmunoCellular.  By virtue of this scheme, the market was conditioned to believe that ImmunoCellular’s clinical studies for ICT-107 were going well as the placement of these fraudulent media reports were often timed to coincide with ImmunoCellular’s announcements of ICT-107, so to have maximum impact upon ImmunoCellular’s share price.

Unbeknownst to the market, beginning in September 2011, ImmunoCellular hired Lidingo Holdings, LLC, a stock promotional firm to pump up the value of ImmunoCellular stock.  This endeavor included a campaign of planting phony analyst reports and news articles that fawned over ImmunoCellular.  In many cases, these phony media reports were written under aliases, and failed to reveal that ImmunoCellular had complete editorial control over their work.

On December 11, 2013, ImmunoCellular revealed that the primary endpoint for its ICT-107 Phase II study "did not reach statistical significance" because it failed to increase overall survival in patients diagnosed with glioblastoma multiforme.

As a result, ImmunoCellular stock declined nearly 60%, to close at $1.10 per share on December 12, 2013.

On April 10, 2017, as part of an SEC proceeding, ImmunoCellular’s former CEO, Manish Singh acknowledged that he participated "in a paid stock-touting scheme" where he "edited and approved articles, directed which writers should publish articles and directed when and where those articles should be published.”   

Wolf Popper has successfully recovered billions of dollars for defrauded investors.  The firm’s reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.  See www.wolfpopper.com. 

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

For more information, please contact:

Robert C. Finkel, Esq.
Tel.: 877.370.7703
Fax: 877.370.7704
Email: [email protected]
website: www.wolfpopper.com